Summary: Battelle utilizes the EpiAirway 3D respiratory tract tissue model for respiratory pathogen infection studies and for comparison of response to infection in the 3D in vitro tissue models derived from normal, asthmatic, smoker, and chronic obstructive pulmonary disease (COPD) donor tissues. Battelle has demonstrated that the EpiAirway tissues can be cultured for extended periods up to 30 days without a significant loss in viability and with high precision. After exposure/infection, cellular cytotoxicity has been quantified by MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetra-zolium bromide, a tetrazole) or biotoxicity assays and cytokine expression has been quantified by cytokine multiplex bead arrays using the Luminex-200 system. Current studies are under way to evaluate the cytotoxic concentrations (CC50) and pathogen inhibitory concentrations (IC50) of several chemotherapeutic compounds. When compared with infected tissues from healthy donors, the 3D airway tissues derived from patients who were asthmatic with COPD exhibited increased viral replication and enhanced infection-induced cellular toxicity and cytokine production. Key Benefits: Rapid screening for identification of lead compounds. Cost reduction associated with more thorough assessments prior to expensive pre-clinical animal studies. Model system for respiratory infections with either viral or bacterial etiologies. System in which to study bacterial/viral-induced disease exacerbations as occur in patients who were asthmatic with COPD. In vitro test system for anti-viral therapeutics and prophylactics


Adenylate kinase, Asthmatic tissue, Chronic obstructive pulmonary disease (COPD), Cytokine expression, EpiAirway, GM-CSF, IL-1rá, IL-1á, IL-1â, IL-6, IL-8, IP-10, Influenza A, MCP-1, MCP-3, MIP-1á, MIP-1â, RANTES, Respiratory infection, Smoker tissue, TNF-á, Viral HA

Materials Tested

Influenza A virus

Request a copy of this paper, click here.